As of Apr 20
| -0.21 / -0.41%|
The 19 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 49.41, with a high estimate of 62.76 and a low estimate of 41.29. The median estimate represents a -2.82% decrease from the last price of 50.84.
The current consensus among 20 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.